Tamoxifen use and endometrial lesions: Hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer

Menopause

Volumn 16, Issue 2, 2009, Pages 293-300

  Dibi, Raquel P ^a,b   Zettler, Claudio G ^a,b   Pessini, Suzana A ^a   Ayub, Alice V ^a   De Almeida, Suzane B ^a   Da Silveira, Gustavo P G ^a,b  

^a Complexo Hospitalar Santa Casa de Porto Alegre ^*  (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Endometrium; Ki 67 Y Estrogen receptor; Menopause; Progesterone receptor; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOMAMMOGRAPHY; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTEROSCOPY; IMMUNOHISTOCHEMISTRY; MEDICAL RECORD; MENOPAUSE; METRORRHAGIA; MYOMA; POSTMENOPAUSE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYSTEROSCOPY; MIDDLE AGED; POLYPS; POSTMENOPAUSE; TAMOXIFEN;

EID: 67649376698     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31818af10a     Document Type: Article

References (66)

1. Mourits MJE, Ten Hoor KA, van der Zee AGJ, Willemse PHB, de Vries EGE, Hollema H. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 2002;55:514-519.
2. Ellis MJ, Hayes DF, Lippman ME. Tratamento do câncer de mama metastático. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Doen0as da Mama, 2nd ed. Rio de Janeiro, Brazil: RJ: Medsi, 2002:897-956.
3. Fornander T, Rutgvist LE, Cedermak B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117-120.
4. IARC. Some Pharmaceutical Drugs. Geneva, Switzerland: World Health Organization; IARC Monographs on the Evaluation of Carcinogenic Risks to Human. 1996;66:253-265.
5. Bergman L, Beelen MLR, Gallee MPW, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000; 356:881-887.
6. Cohen I, Perel E, Flex D, et al. Endometrial pathologies in postmenopausal tamoxifen treatment: comparison between gynaecological symptomatic and gynaecological asymptomatic breast cancer patients. J Clin Pathol 1999;52:278-282.
7. Gon0alves MA, Gon0alves WJ, Matias MM, Nazario AC, De Lima GR, Baracat EC. Hysteroscopic evaluation of the endometrium of postmenopausal patients with breast cancer before and after tamoxifen use. Int J Gynaecol Obstet 1999;66:273-279.
8. Gebauer G, Hafner A, Siebzehnrubl E, Lang N. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol 2001;184:59-63.
9. Symonds I. Ultrasound, hysteroscopy and endometrial biopsy in the investigation of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001;15:381-391.
10. Garuti G, Grossi F, Cellani F, Centinaio G, Colonnelli M, Luerti M. Hysteroscopic assessment of menopausal breast-cancer patients taking tamoxifen; there is a bias from the mode of endometrial sampling in estimating endometrial morbidity? Breast Cancer Res Treat 2002; 72:245-253.
11. Brown DC, Gatter KC. Ki-67 protein: the immaculate deception? Histopathology 2002;40:2-11.
12. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000;257:231-237.
13. The North American Menopause Society. Definitions and statistics. Available at: http://www.menopause.org/aboutmeno/overview.htm. Accessed December 18, 2006.
14. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000;78:181-186.
15. Cohen I, Rosen DJ, Shapira J, et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic postmenopausal breast cancer patients. Gynecol Oncol 1994;52: 185-190.
16. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17:2050-2054.
17. Dijkhuizen FP, Brolmann HA, Oddens BJ, Roumen RM, Coebergh JW, Heintz AP. Transvaginal ultrasonography and endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Maturitas 1996;25:45-50.
18. Cohen I, Rosen DJ, Tepper R, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993;12: 275-280.
19. Kavak ZN, Binoz S, Ceyhan N, Pekin S. The effect of tamoxifen on the endometrium, serum lipids and hypothalamus pituitary axis in the postmenopausal breast cancer patients. Acta Obstet Gynecol Scand 2000;79:604-607.
20. Ascher SM, Johnson JC, Barnes WA, Bae CJ, Patt RH, Zeman RK. MR imaging appearance of the uterus in postmenopausal women receiving tamoxifen therapy for breast cancer: histopathologic correlation. Radiology 1996;200:105-110.
21. Zarbo G, Caruso G, Zammitti M, Caruso S, Zarbo R. The effects of tamoxifen therapy on the endometrium. Eur J Gynaecol Oncol 2000;21: 86-88.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:15451-15467.
23. da Silveira GPG, ed. Ginecologia Baseada em Evidências, 1st ed. São Paulo, Brazil: Atheneu, 2004.
24. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256-266.
25. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664.
26. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet 1989;2:375.
27. Cohen I, Altaras MM, Shapira J, Beyth Y. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen. Gynecol Obstet Invest 1997;43:60-63.
28. Cheng W-F, Lin H-H, Torng P-L, Huang S.-C. Comparison of endometrial changes among symptomatic tamoxifen-treated and non-treated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66:233-237.
29. Maugeri G, Nardo LG, Campione C, Nardo F. Endometrial lesions after tamoxifen therapy in breast cancer women. Breast J 2001;7:240-244.
30. McGonigle KF, Shaw SL, Vasilev SA et al. Abnormalities detected on transvaginal ultrasonography in tamoxifen treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998;178:1145-1150.
31. Biron-Shental T, Tepper R, Fishman A, Saphira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol 2003;90:382-386.
32. Senkus-Konefka E, Konefka T, Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004;30:291-301.
33. Cohen I, Azaria R, Shapira J, Yigael D, Tepper R. The significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer 2000;94:3101-3106.
34. Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B. Endometrial polyps in PM patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-131.
35. Gerber B, Krause A, Muller H et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000;18:3464-3470.
36. Neven P, De Muylder X, Van Belle Y, Van Hooff I, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 1998;351:36.
37. Cohen I, Azaria R, Fishman A, Tepper R, Saphira J, Beyth Y. Endometrial cancer in postmenopausal breast cancer patients with tamoxifen treatment. Int J Gynecol Pathol 1999;18:304-309.
38. Ceci O, Bettocchi S, Marello F, et al. Hysteroscopic evaluation of the endometrium in postmenopausal women taking tamoxifen. J Am Assoc Gynecol Laparosc 2000;7:185-189.
39. Ramondetta LM, Sherwood JB, Dunton CJ, Palazzo JP. Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol 1999; 180:340-341.
40. Cohen I, Bernheim J, Azaria R, Tepper R, Sharoney R, Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 1999;75:136-141.
41. Tepper R, Beyth Y, Altaras MM, et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 1997;64:386-391.
42. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systemic pretreatment screening. Obstet Gynecol 1998;191:40-44.
43. Taylor LJ, Jackson TL, Reid JG, Duffy SRG. The differential expression of estrogen receptors, progesterone receptors, Bcl-2 and Ki-67 in endometrial polyps. BJOG 2003;110:794-798.
44. McGurgan P, Taylor LJ, Duffy SRG, O'Donovan PJ. Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen. Maturitas 2006;54:252-259.
45. Willen R, Lindhal B, Andolf E, Ingvar C, Liedman R, Ranstam J. Histopathologic findings in thickened endometria, as measured by ultrasound, in asymptomatic postmenopausal breast cancer patients on various adjuvant treatment including tamoxifen. Anticancer Res 1998;18:667-676.
46. Gal D, Kopel S, Bashevkin M. Oncogenic potential of tamoxifen on endometrium of postmenopausal women with breast cancer: a preliminary report. Gynecol Oncol 1991;42:120-123.
47. McGonigle KF, Smith DD, Marx HF, et al. Uterine effects of tamoxifen: a prospective study. Int J Gynecol Cancer 2006;16:814-820.
48. Borenstein J, Ausllender R, Pascal B, et al. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J ReprodMed 1994;39:674-678.
49. Gibson LE, Barakat RR, Venkatraman ES. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and non-users. Cancer J 1996;2:35-38.
50. Hann LE, Geiss CS, Bach AM, Tao Y, Baum HJ, Barakat RR. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. Am J Roentgenol 1997;168:657-661.
51. Marconi D, Exacoustos C, Cangi B, et al. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. J Am Assoc Gynecol Laparosc 1997;4:331-339.
52. Mignotte H, Lasset C, Bonadona V, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998;76:325-330.
53. Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993;85:1850-1855.
54. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronim WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
55. Anderson M, Storm HH, Mouridsen HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 1992;31:259-263.
56. Van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast. Lancet 1994;343: 1448-1452.
57. Adami HO, Bergstrom R, Weiderpass E, et al. Risk for endometrial cancer following breast cancer: a prospective study in Sweden. Cancer Causes Control 1997;8:821-827.
58. Van Leeuwen FE, Bergman L, Beelen ML, Gallee M, Hollema H. Tamoxifen and risk of endometrial cancer. Lancet 2001;357:67.
59. Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancer. J Natl Cancer Inst 1995;87:1359-1364.
60. Le Donne M, Lentini M, De Meo L, Benedetto V, Mesiti M. Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings. Eur J Gynae-col Oncol 2005;26:623-626.
61. Bergman L, Beelen ML, Galee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000;356:881-887.
62. Dallenbach-Hellweg G, Schmidt D, Hellberg P, et al. The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet 2000;263: 170-177.
63. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11:485-490.
64. ACOG Committee Opinion. Tamoxifen and endometrial cancer, number 336, June 2006. American College of Obstetricians and Gynecologists. Obstet Gynecol 2006;107:1475-1478.
65. Varras M, Polyzos D, Akrivis Ch. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003;24:258-268.
66. Cohen I, Perel E, Flex D, et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecological symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999;52:278-282.